Novartis AG
$147.76
▼
-0.14%
2026-04-22 10:12:13
www.novartis.com
NYQ: NVS
Explore Novartis AG stock price, valuation, financial statements, dividend history, analyst estimates, and long-term business fundamentals on StockSifting.
Market Cap
$301.93 B
Current Price
$147.76
52W High / Low
$131 / $87.89
Stock P/E
20.66
Book Value
$24.18
Dividend Yield
3.13%
ROCE
21.09%
ROE
30.81%
Face Value
—
EPS
$7.15
Exp Qtr EPS
—
Sector
Healthcare
Industry
Drug Manufacturers - General
Employees
75,267
Beta
0.52
Debt / Equity
76.17
Current Ratio
1.12
Quick Ratio
0.89
Forward P/E
15.67
Price / Sales
5.25
Enterprise Value
$318.29 B
EV / EBITDA
13.56
EV / Revenue
5.62
Rating
Hold
Target Price
$153.26
EPS Forecast (FY)
—
Pros
- Healthy return on equity.
- Efficient use of capital employed.
- Strong operating margin profile.
- Net margin remains healthy.
- Meaningful dividend yield is available.
Cons
- Some data points may be missing or delayed because the source is not an official exchange feed.
Sift Stocks
| S.No. | Name | Price | P.E. | Market Cap | Div Yld % | ROCE | ROE | 52Week High/ Low | Book Value |
|---|---|---|---|---|---|---|---|---|---|
| 1. | Eli Lilly and Company | $921 | 40.12 | $868.52 B | 0.75% | 38.44% | 1.01% | $1,133.95 / $623.78 | $29.66 |
| 2. | Gilead Sciences, Inc. | $133.45 | 19.68 | $165.41 B | 2.41% | 24.79% | 40.66% | $157.29 / $93.37 | $18.29 |
| 3. | Novo Nordisk A/S | $39.12 | 10.82 | $131.02 B | 4.54% | 39.01% | 60.7% | $533.4 / $224.25 | $6.83 |
| 4. | Nasus Pharma Ltd. | $2.86 | — | $19.29 M | — | -172.62% | 2637.84% | $9.99 / $1.98 | $0.31 |
| 5. | MIRA Pharmaceuticals, Inc. | $1.12 | — | $47.06 M | — | -100.98% | -1.66% | $2.45 / $0.83 | $0.25 |
| 6. | AstraZeneca PLC | $196.47 | 30 | $305.64 B | 1.58% | 15.97% | 22.84% | $15,730 / $9,651 | $31.38 |
| 7. | Scilex Holding Company | $6.95 | — | $58.97 M | — | 55.67% | 39.83% | $34.27 / $3.6 | $-29.75 |
Quarterly Results
Figures shown in M / B
| Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | |
|---|---|---|---|---|---|
| Sales | 13.86 B | 14.36 B | 14.84 B | 13.62 B | 13.56 B |
| Operating Profit | 3.62 B | 4.5 B | 4.86 B | 4.66 B | 3.53 B |
| Net Profit | 2.41 B | 3.93 B | 4.04 B | 3.61 B | 2.82 B |
| EPS in Rs | 1.26 | 2.06 | 2.12 | 1.89 | 1.48 |
Profit & Loss
Figures shown in M / B
| 2025 | 2024 | 2023 | 2022 | |
|---|---|---|---|---|
| Sales | 56.67 B | 51.72 B | 46.66 B | 43.46 B |
| Operating Profit | 17.64 B | 14.54 B | 9.77 B | 7.95 B |
| Net Profit | 13.98 B | 11.94 B | 14.85 B | 6.96 B |
| EPS in Rs | 7.33 | 6.26 | 7.78 | 3.64 |
Balance Sheet
Figures shown in M / B
| 2025 | 2024 | 2023 | 2022 | |
|---|---|---|---|---|
| Total Assets | 110.95 B | 102.25 B | 99.94 B | 117.45 B |
| Total Liabilities | 64.4 B | 58.12 B | 53.2 B | 58.03 B |
| Equity | 46.13 B | 44.05 B | 46.67 B | 59.34 B |
| Current Assets | 30.46 B | 29.7 B | 30.48 B | 36.91 B |
| Current Liabilities | 27.28 B | 28.69 B | 26.39 B | 28.66 B |
Cash Flow
Last available yearly cash flow history
| 2025 | 2024 | 2023 | 2022 | |
|---|---|---|---|---|
| Operating CF | 19.14 B | 17.62 B | 14.46 B | 14.24 B |
| Investing CF | -4.88 B | -7.51 B | 5.6 B | 1.47 B |
| Financing CF | -14.87 B | -11.74 B | -14.28 B | -20.56 B |
| Free CF | 15.24 B | 13.8 B | 11.71 B | 12 B |
| Capex | -3.9 B | -3.81 B | -2.75 B | -2.24 B |
5Y Margin & Growth History
Last 5 year derived history from yfinance annual statements
| 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|
| Revenue Growth % | 10.85% | 7.36% | — | — |
| Earnings Growth % | -19.59% | 113.52% | — | — |
| Profit Margin % | 23.09% | 31.83% | 16% | — |
| Operating Margin % | 28.12% | 20.94% | 18.28% | — |
| Gross Margin % | 75.2% | 73.27% | 73.35% | — |
| EBITDA Margin % | 40.05% | 39.12% | 33.78% | — |
Dividend & Split History
Latest dividend and stock split events stored from yfinance
Dividend History
| Ex Date | Dividend |
|---|---|
| 2026-03-11 | $4.773 |
| 2025-03-12 | $3.994 |
| 2024-03-07 | $3.74 |
| 2023-03-09 | $3.469 |
| 2022-03-08 | $3.357 |
Stock Splits
No stock split history available.